2025 has been a seismic year for the pharmaceutical industry, a year of extremes where innovation superpowers emerge alongside spectacular collapses. In this special episode, BioBiz Buzz host Jo Shorthouse sits down with Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership at Clarivate, fresh from his opening keynote at One Nucleus's landmark Genesis conference in London. Join us as Mike dissects the winners and losers reshaping pharma's landscape: Eli Lilly's historic as...
All content for BioBiz Buzz is the property of https://biobizbuzz.com/ and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
2025 has been a seismic year for the pharmaceutical industry, a year of extremes where innovation superpowers emerge alongside spectacular collapses. In this special episode, BioBiz Buzz host Jo Shorthouse sits down with Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership at Clarivate, fresh from his opening keynote at One Nucleus's landmark Genesis conference in London. Join us as Mike dissects the winners and losers reshaping pharma's landscape: Eli Lilly's historic as...
13. Tackling the undruggable: How Beactica's protein degradation platform might transform glioblastoma treatment
BioBiz Buzz
31 minutes
2 months ago
13. Tackling the undruggable: How Beactica's protein degradation platform might transform glioblastoma treatment
Targeted protein degradation (TPD) represents one of the most transformative advances in drug discovery, with the global market projected to expand from USD 641 million in 2025 to as much as USD 9.85 billion by 2035. This rapidly evolving field enables researchers to eliminate disease-causing proteins rather than merely inhibiting their function, offering unprecedented opportunities to tackle previously "undruggable" targets that have eluded conventional therapeutic approaches with the ...
BioBiz Buzz
2025 has been a seismic year for the pharmaceutical industry, a year of extremes where innovation superpowers emerge alongside spectacular collapses. In this special episode, BioBiz Buzz host Jo Shorthouse sits down with Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership at Clarivate, fresh from his opening keynote at One Nucleus's landmark Genesis conference in London. Join us as Mike dissects the winners and losers reshaping pharma's landscape: Eli Lilly's historic as...
